3-甲基茚-2-羧酸 | 34225-81-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 中文名称: 3-甲基茚-2-羧酸
• 英文名称: 3-methyl-1H-indene-2-carboxylic acid
• 英文别名: 3-methylindene-2-carboxylic acid；3-Methyl-inden-2-carbonsaeure；1-Methyl-inden-2-carbonsaeure
• CAS: 34225-81-5
• 化学式: C₁₁H₁₀O₂
• mdl: MFCD00044428
• 分子量: 174.199
• InChiKey: RONBYWGSEXDEKC-UHFFFAOYSA-N

物化性质

• 熔点：
  201-203 °C(lit.)
• 沸点：
  306.9±21.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  3-甲基茚-2-羧酸 在 tris-(dibenzylideneacetone)dipalladium(0) 、 1-碘丁烷 、 1,8-双二甲氨基萘 、 chloro-N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以75%的产率得到2-iodo-3-methyl-1H-indene
  参考文献：
  名称：

  通过配体辅助卤化物交换实现芳基羧酸的钯催化脱羰碘化

  摘要：

  我们报道了一种高效且广泛适用的钯催化碘化方法，通过原位活化酰基氯并形成鏻盐，对廉价且丰富的芳基和乙烯基羧酸进行碘化。使用 1-碘丁烷作为碘化物源，与碱和脱氧氯化试剂结合使用，可以在 Pd/Xantphos 催化下获得各种芳基和乙烯基碘化物，包括复杂的药物样支架。化学计量实验和动力学分析表明了一种独特的机制，涉及 C−P 还原消除以形成 Xantphos 氯化鏻，随后通过外球亲核取代引发不寻常的卤素交换。

  DOI：

  10.1002/anie.202103269
• 作为产物：
  描述：

  2-苄基-3-氧代丁酸 在 三氟甲磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 以70%的产率得到3-甲基茚-2-羧酸
  参考文献：
  名称：

  Cyclization of Arylacetoacetates to Indene and Dihydronaphthalene Derivatives in Strong Acids. Evidence for Involvement of Further Protonation of O,O-Diprotonated β-Ketoester, Leading to Enhancement of Cyclization

  摘要：

  The chemical features, such as substrate stability, product distribution, and substrate generality, and the reaction mechanism of Bronsted superacid-catalyzed cyclization reactions of aromatic ring-containing acetoacetates (beta-ketoesters) were examined in detail. While two types of carbonyl cyclization are possible, i.e., keto cyclization and ester cyclization, the former was found to take place exclusively. The reaction constitutes an efficient method to synthesize indene and 3,4-dihydronapthalene derivatives. Acid-base titration monitored with C-13 NMR spectroscopy showed that the acetoacetates are fully O-1,O-3-diprotonated at H-0 = -11. While the five-membered ring cyclization of the arylacetoacetates proceeded slowly at H-0 = -11, a linear increase in the rate of the cyclization was found with increasing acidity in the high acidity region of H-0 = -11.8 to -13.3. Therefore, the O-1,O-3-diprotonated acetoacetates exhibited some cyclizing reactivity, but they are not the reactive intermediates responsible for the acceleration of the cyclization in the high acidity region. The reactive cationic species might be formed by further protonation (or protosolvation) of the O-1,O-3-diprotonated acetoacetates; i.e., they may be tricationic species. Thermochemical data on the acid-catalyzed cyclization of the arylacetoacetates showed that the activation energy is decreased significantly as compared with that of the related acid-catalyzed cyclization reaction of a compound bearing a single functional group, such as a ketone. These findings indicate that intervention of the trication contributes to the activation of the cyclization of arylacetoacetates in strong acid, and the electron-withdrawing nature of the O-protonated ester functionality significantly increases the electrophilicity of the ketone moiety.

  DOI：

  10.1021/ja908749u

文献信息

• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] BENZIMIDAZOLE OR INDOLE AMIDES AS INHIBITORS OF PIN1<br/>[FR] AMIDES DE BENZIMIDAZOLE OU D'INDOLE EN TANT QU'INHIBITEURS DE PIN1
  申请人：PFIZER

  公开号：WO2006040646A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts and solvates thereof, wherein the variables are defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (1) and to pharmaceutical compositions for treating such disorders that contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).

  这项发明涉及公式（1）的化合物，以及其药学上可接受的盐和溶剂化合物，其中变量在此处定义。该发明还涉及通过给予公式（1）的化合物来治疗哺乳动物中的异常细胞生长的方法，以及用于治疗包含公式（1）化合物的这类疾病的药物组合物。该发明还涉及制备公式（1）化合物的方法。
• Immunoproteasome Inhibitor–Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation
  作者：Elmer Maurits、Michel J. van de Graaff、Santina Maiorana、Dennis P. A. Wander、Patrick M. Dekker、Sabina Y. van der Zanden、Bogdan I. Florea、Jacques J. C. Neefjes、Herman S. Overkleeft、Sander I. van Kasteren

  DOI：10.1021/jacs.9b11969

  日期：2020.4.22

  are anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug classes into a single molecule. Doxorubicin was conjugated to an immunoproteasome-selective inhibitor via light-cleavable linkers, yielding peptide epoxyketone–doxorubicin prodrugs that remained selective and active toward immunoproteasomes. Upon cellular uptake and immunoproteasome inhibition

  蛋白酶体抑制剂是治疗血液系统癌症的公认治疗剂，蒽环类药物如阿霉素也是如此。我们在这里提出了一种新的药物靶向方法，它将两种药物类别结合到一个分子中。多柔比星通过光可裂解接头与免疫蛋白酶体选择性抑制剂偶联，产生肽环氧基酮-多柔比星前药，该前药对免疫蛋白酶体保持选择性和活性。在细胞摄取和免疫蛋白酶体抑制后，多柔比星通过光照射从免疫蛋白酶体抑制剂中释放出来。多发性骨髓瘤细胞以这种方式受到双重打击：免疫蛋白酶体抑制和阿霉素诱导的毒性。我们的策略需要靶向细胞毒剂，
• Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
  作者：B. E. Evans、K. E. Rittle、M. G. Bock、R. M. DiPardo、R. M. Freidinger、W. L. Whitter、G. F. Lundell、D. F. Veber、P. S. Anderson、R. S. L. Chang、V. J. Lotti、D. J. Cerino、T. B. Chen、P. J. Kling、K. A. Kunkel、J. P. Springer、J. Hirshfield

  DOI：10.1021/jm00120a002

  日期：1988.12.1

  3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described. Developed by reasoned modification of the known anxiolytic benzodiazepines, these compounds provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8. The distinction

  描述了肽激素胆囊收缩素（CCK）的拮抗剂3-（酰基氨基）-5-苯基-2H-1,4-苯并二氮杂s。通过合理修饰已知的抗焦虑苯二氮卓类药物开发而成的这些化合物提供了对外周（CCK-A）受体具有选择性的高效，口服有效的配体，其结合亲和力接近或等于天然配体CCK-8。通过使用新化合物的结构活性图，可以证明一方面是CCK-A受体，另一方面是CNS（CCK-B），胃泌素和中心苯二氮卓类受体。研究了这些药物与CCK-A受体结合的细节，并就其与药物开发的一般问题的相关性讨论了这些化合物的开发方法。
• A Linker for the Solid-Phase Synthesis of Hydroxamic Acids and Identification of HDAC6 Inhibitors
  作者：Claus G. Bang、Jakob F. Jensen、Emil O’Hanlon Cohrt、Lasse B. Olsen、Saba G. Siyum、Kim T. Mortensen、Tine Skovgaard、Jens Berthelsen、Liang Yang、Michael Givskov、Katrine Qvortrup、Thomas E. Nielsen

  DOI：10.1021/acscombsci.7b00068

  日期：2017.10.9

  readily available and nonintegral hydroxylamine linkers for the routine solid-phase synthesis of hydroxamic acids. The developed protocols enable the efficient synthesis and release of a wide range of hydroxamic acids from various resins, relying on high control and flexibility with respect to reagents and synthetic processes. A trityl-based hydroxylamine linker was used to synthesize a library of peptide

  我们在此提出了广泛有用的，容易获得的和非整体的羟胺连接基，用于羟肟酸的常规固相合成。所开发的方案能够有效地从各种树脂合成和释放各种异羟肟酸，这取决于试剂和合成方法的高度控制和灵活性。基于三苯甲基的羟胺接头用于合成肽异羟肟酸的文库。使用基于化学发光的测定法检查了化合物对7种HDAC酶亚型的抑制作用。

表征谱图